Baseline characteristics
high-density lipoprotein
Two hundred patients were included between 16 March 2017 and 13 February 2020. One patient withdrew consent. Accordingly, we present data from 199 patients, 98 in the placebo group and 101 patients in the tocilizumab group. Baseline characteristics are summarised in Baseline characteristics stratified by treatment allocationValues are n (%).*Mean±SD.†Median (IQR).ARB, angiotensin receptor; CK-MB, creatine kinase myocardial band; CRP, C reactive protein; DAPT, dual antiplatelet therapy; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention.